← Back to Search

Continuous Glucose Monitoring

Continuous glucose monitoring (CGM) arm for Hemodialysis (CONDOR Trial)

N/A
Recruiting
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥18 years old
Type 1 or type 2 diabetes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

CONDOR Trial Summary

This trial will compare the use of continuous glucose monitoring (CGM) to regular blood glucose monitoring in patients with diabetes who are undergoing hemodialysis. The trial aims to determine if CGM can improve

Who is the study for?
This trial is for adults over 18 with end-stage kidney disease on hemodialysis and diabetes, who have been checking their blood sugar themselves for at least 4 weeks. They must be willing to wear a continuous glucose monitoring device and have done so with good compliance in the pre-trial period.Check my eligibility
What is being tested?
The study compares two ways of monitoring blood sugar in dialysis patients with diabetes: one group will use continuous glucose monitors (CGM), while the other will stick to self-monitoring. The goal is to see if CGMs can better control blood sugar levels, reduce low blood sugar episodes, and improve overall well-being.See study design
What are the potential side effects?
While not explicitly stated here, potential side effects from using CGM may include skin irritation or infection at the sensor site. Usual care through self-monitoring typically has minimal risks like discomfort or bruising from finger pricks.

CONDOR Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have diabetes.
Select...
I have been checking my blood sugar levels by myself for at least 4 weeks.

CONDOR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent (%) of time in target glucose range (70-180 mg/dl)
Secondary outcome measures
Diabetes Distress Scale Survey Score
Fructosamine level
Glycated albumin level
+6 more
Other outcome measures
Continuous glucose monitoring compliance during the intervention period
Participant feedback on continuous glucose monitoring training sessions

CONDOR Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Continuous glucose monitoring (CGM) armExperimental Treatment1 Intervention
During the intervention period, patients in the CGM arm will undergo continuous real-time "unblinded" CGM using Dexcom CGM devices.
Group II: Usual care armActive Control1 Intervention
During the intervention period, patients in the usual care arm will conduct self-monitored blood glucose (SMBG) at least 4 times/day. At Weeks 6 and 12 of the intervention period, usual care arm patients will also undergo 10-days of blinded CGM data collection.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Continuous glucose monitoring (CGM)
2016
Completed Phase 4
~230

Find a Location

Who is running the clinical trial?

University of California, IrvineLead Sponsor
546 Previous Clinical Trials
1,923,079 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,378 Previous Clinical Trials
4,315,349 Total Patients Enrolled
~81 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top